STOCK TITAN

60 Degrees Pharmaceuticals (SXTP) CEO boosts holdings with stock buy

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals reported that President and CEO Geoffrey Dow, who is also a director, bought 9,670 shares of its common stock on December 15, 2025 at $0.8024 per share. Following this purchase, he directly owns 59,618 common shares of the company.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DOW GEOFFREY S

(Last) (First) (Middle)
C/O 60 DEGREES PHARMACEUTICALS, INC.
1025 CONNECTICUT AVENUE NW SUITE 1000

(Street)
WASHINGTON DC 20036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 P 9,670 A $0.8024 59,618 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Geoffrey Dow 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 60 Degrees Pharmaceuticals (SXTP) disclose?

The company disclosed that President and CEO Geoffrey Dow purchased 9,670 shares of its common stock on December 15, 2025 at a price of $0.8024 per share.

Who is the reporting person in this SXTP insider transaction?

The reporting person is Geoffrey Dow, who serves as President, CEO, and Director of 60 Degrees Pharmaceuticals, Inc.

How many 60 Degrees Pharmaceuticals shares does the CEO own after the trade?

After the reported transaction, Geoffrey Dow directly owns 59,618 shares of 60 Degrees Pharmaceuticals common stock.

Was the SXTP insider position reported as direct or indirect ownership?

The filing shows the 59,618 shares as held with direct (D) ownership by Geoffrey Dow.

On what date did the SXTP insider stock purchase occur?

The purchase of 9,670 shares of 60 Degrees Pharmaceuticals common stock occurred on December 15, 2025.

What type of security did the 60 Degrees Pharmaceuticals CEO acquire?

Geoffrey Dow acquired shares of common stock of 60 Degrees Pharmaceuticals, Inc.

60 degrees pharmaceuticals, Inc.

NASDAQ:SXTP

SXTP Rankings

SXTP Latest News

SXTP Latest SEC Filings

SXTP Stock Data

3.12M
4.12M
2.96%
12.89%
2.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
WASHINGTON